PuSH - Publikationsserver des Helmholtz Zentrums München

Morgen, M.* ; Jöst, C.* ; Malz, M.* ; Janowski, R. ; Niessing, D. ; Klein, C.D.* ; Gunkel, N.* ; Miller, A.K.*

Spiroepoxytriazoles are fumagillin-like irreversible inhibitors of MetAP2 with potent cellular activityγ.

ACS Chem. Biol. 11, 1001-1011 (2016)
Verlagsversion Postprint DOI
Open Access Green
Methionine aminopeptidases (MetAPs) are responsible for the co-translational cleavage of initiator methionines from nascent proteins. The MetAP2 subtype is up-regulated in many cancers, and selective inhibition of MetAP2 suppresses both vascularization and growth of tumors in animal models. The natural product fumagillin is a selective and potent irreversible inhibitor of MetAP2, and semi-synthetic derivatives of fumagillin have shown promise in clinical studies for the treatment of cancer, and, more recently, for obesity. Further development of fumagillin derivatives has been complicated, however, by their generally poor pharmacokinetics. In an attempt to overcome these limitations, we developed an easily diversifiable synthesis of a novel class of MetAP2 inhibitors that were designed to mimic fumagillin's molecular scaffold but have improved pharmacological profiles. These substances were found to be potent and selective inhibitors of MetAP2, as demonstrated in biochemical enzymatic assays against three MetAP isoforms. Inhibitors with the same relative and absolute stereoconfiguration as fumagillin displayed significantly higher activity than their diastereomeric and enantiomeric isomers. X-ray crystallographic analysis revealed that the inhibitors covalently modify His231 in the MetAP2 active site via ring-opening of a spiroepoxide. Biochemically active substances inhibited the growth of endothelial cells and a MetAP2-sensitive cancer cell line, while closely related inactive isomers had little effect on the proliferation of either cell type. These effects correlated with altered N-terminal processing of the protein 14-3-3-γ. Finally, selected substances were found to have improved stabilities in mouse plasma and microsomes relative to the clinically-investigated fumagillin derivative beloranib.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Methionine Aminopeptidase Inhibitors; Angiogenesis Inhibitors; Chemical-modification; Antiangiogenic Agent; Synthetic Analogs; Growth Arrest; Phase-i; Tnp-470; Ovalicin; Design
ISSN (print) / ISBN 1554-8929
e-ISSN 1554-8937
Zeitschrift ACS Chemical Biology
Quellenangaben Band: 11, Heft: 4, Seiten: 1001-1011 Artikelnummer: , Supplement: ,
Verlag American Chemical Society (ACS)
Verlagsort Washington
Begutachtungsstatus Peer reviewed